Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Artificial intelligence focused on dynamic patient care is helping to fine-tune drug dosing regimes and reduce hospital wait times, with potentially dramatic benefits.
Families of paediatric cancer patients have helped move a pioneering treatment for neuroblastoma from the lab to the clinic. Could this breakthrough accelerate the development of future treatments?
How does the brain control how much we eat, and — conversely — how does the gut impact our brain health? Researchers are revealing some interesting findings.
The efficacy and safety of a treatment is best confirmed in the real world through post-marketing data collection according to pharmaceutical company Alexion Japan.
MD Anderson leads the way in combining microbiome insights with cancer therapy, revealing how dietary interventions can transform patient outcomes and advance precision medicine.
The progression of chronic kidney disease can take patients and doctors by surprise. But if public awareness about the risks of this potential killer changes, the prognosis for patients could too.
Targeting IL-17 signalling as a cancer therapy can trigger an imbalance in gut microbiota that fuels tumour growth, but the right antibiotics could break this damaging feedback loop.
As the science behind a novel approach to treating disease evolves, the focus of research and clinical development is expanding from rare conditions to far more common diseases.
With the life science park as the jewel in its crown, the life sciences zone in the Changping district of Beijing is growing and branching out into novel areas of research and development.